NCT03302546

Brief Summary

The Hemodialysis Unit of the Hospital Ramon y Cajal is a pioneer in the implementation of a program of incremental hemodialysis, starting with two sessions a week in patients with residual renal function. The main objective is to compare whether the initiation of hemodialysis with two sessions a week over conventional pattern of initiation of three sessions a week better preserves residual renal function.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 4, 2017

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 3, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

October 5, 2017

Completed
5.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
Last Updated

May 13, 2024

Status Verified

May 1, 2024

Enrollment Period

5.7 years

First QC Date

July 3, 2017

Last Update Submit

May 10, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Asses the loss of residual renal function in patients who started chronic hemodialysis

    Assess the loss of renal function evolution in patients starting hemodialysis therapy 2 days per week, versus patients with hemodialysis 3 days per week.

    Measurements of multiple variables to measure renal function each two months during one year period

Study Arms (2)

Incremental Hemodialysis

ACTIVE COMPARATOR

Subjects on this arm will be treated with 2 hemodialysis sessions of at least 4 hour per week.

Procedure: Incremental hemodialysis

Conventional hemodialysis

ACTIVE COMPARATOR

Subjects on this arms will be treated with 3 hemodialysis sessions of at least 3.5 hour per week.

Procedure: Conventional hemodialysis

Interventions

Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week

Incremental Hemodialysis

Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week

Conventional hemodialysis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects starting renal replacement therapy from January 2017 to June 2018.
  • Subjects who consent to sign the Informed Consent Form.
  • Subject who maintain residual diuresis and urea clearance equal or superior to 2,5 ml/min.

You may not qualify if:

  • Anuric patients.
  • Patients with acute renal failure.
  • Patients who revoke the Informed Consent Form.
  • Patients who start hemodialysis after having going through a renal transplant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Ramón y Cajal

Madrid, 28034, Spain

Location

Related Publications (1)

  • Fernandez Lucas M, Ruiz-Roso G, Merino JL, Sanchez R, Bouarich H, Herrero JA, Muriel A, Zamora J, Collado A. Initiating renal replacement therapy through incremental haemodialysis: Protocol for a randomized multicentre clinical trial. Trials. 2020 Feb 19;21(1):206. doi: 10.1186/s13063-020-4058-0.

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 3, 2017

First Posted

October 5, 2017

Study Start

April 4, 2017

Primary Completion

December 30, 2022

Study Completion

December 30, 2022

Last Updated

May 13, 2024

Record last verified: 2024-05

Locations